Stock Events

Stock Events

Atyr Pharma

0

295

+€0.00+0% 00:00 Today

Statistics

Day High

-

Day Low

-

52W High

-

52W Low

-

Volume

-

Avg. Volume

-

Mkt Cap

0

P/E Ratio

-

Dividend Yield

-

Dividend

-

Upcoming

Earnings

5NovExpected

Q1 2026

Q2 2026

Next

-0.11

-0.1

-0.1

-0.09

Expected EPS

-0.08602

Actual EPS

N/A

Financials

14.75%Profit Margin

Profitable

2020

2021

2022

2023

2024

2025

329.54MRevenue

48.61MNet Income

Analyst Ratings

19.67Average Price Target

The highest estimate is 28.08.
From 6 ratings within the last 6 months. This is not an investment recommendation.

Buy

83%

Hold

17%

Sell

0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 471.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals competes in the biopharmaceutical space, focusing on immunology and inflammatory diseases, similar to aTyr Pharma's focus on immune modulation for various diseases.

Amgen operates in the same biotech space, developing therapies for serious illnesses, including those related to immune system disorders, overlapping with aTyr Pharma's therapeutic areas.

Gilead Sciences

Gilead Sciences is involved in the discovery, development, and commercialization of innovative therapeutics in areas of unmet medical need, including inflammatory and respiratory diseases, competing with aTyr Pharma's pipeline.

Biogen focuses on neurology, autoimmune and hematologic disorders, but its expansion into novel therapeutic areas and biologics can pose competition to aTyr Pharma's novel biologic therapies.

Vertex Pharmaceuticals

Vertex Pharmaceuticals targets serious diseases with its drugs, including cystic fibrosis, which involves managing inflammation and immune response, areas aTyr Pharma is also exploring.

AbbVie works on advanced therapies in immunology, oncology, and virology, including treatments for inflammatory diseases, directly competing with aTyr Pharma's focus on immune modulation.

Novartis offers a broad range of healthcare products in pharmaceuticals, including treatments for autoimmune diseases and inflammation, making it a competitor in the same therapeutic areas as aTyr Pharma.

Pfizer's wide range of therapeutic areas, including inflammation and immunology, puts it in direct competition with aTyr Pharma, especially with its focus on innovative treatments for diseases.

Merck operates in various therapeutic areas, including immunology, and its research into novel therapies for immune-mediated diseases competes with aTyr Pharma's focus.

AstraZeneca has a diverse portfolio in respiratory, cardiovascular, renal, metabolism, and immunology, including therapies for inflammation and autoimmune diseases, competing with aTyr Pharma's research and development focus.

About

aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).

Show more...

CEO

Sanjay S. Shukla

Employees

58

Country

United States

ISIN

US0021201035

WKN

000A2PM86

Listings

0 Comments

Share your thoughts

FAQ

What is Atyr Pharma stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Atyr Pharma stocks are traded under the ticker 471.STU.

When is the next Atyr Pharma earnings date?▼

Atyr Pharma is going to release the next earnings report on November 05, 2026.

What were Atyr Pharma earnings last quarter?▼

471.STU earnings for the last quarter are -0.1 EUR per share, whereas the estimation was -0.11 EUR resulting in a +9.41% surprise. The estimated earnings for the next quarter are N/A EUR per share.

What is Atyr Pharma revenue for the last year?▼

Atyr Pharma revenue for the last year amounts to 329.54M EUR.

What is Atyr Pharma net income for the last year?▼

471.STU net income for the last year is 48.61M EUR.

How many employees does Atyr Pharma have?▼

As of September 04, 2026, the company has 58 employees.

In which sector is Atyr Pharma located?▼

Atyr Pharma operates in the Health & Wellness sector.

When did Atyr Pharma complete a stock split?▼

The last stock split for Atyr Pharma was on July 02, 2019 with a ratio of 1:14.

Where is Atyr Pharma headquartered?▼

Atyr Pharma is headquartered in SAN DIEGO, United States.